secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0001493152-23-005024
Event type: earnings
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharma Q3 revenue $9.3M (+3% YoY), net income $2.96M
----------------------------------------------------------

- Q3 FY2023 revenue $9.3M, up 3% from prior year; operating profit $2.0M.
- Net income for Q3 was $2.96M; nine-month net income $4.79M.
- Nine-month revenue $25.5M (+4% YoY); operating profit $4.1M (down $0.1M).
- Growth driven by generic immediate-release and extended-release Adderall.
- Conference call set for Feb 15, 2023 at 11:30 AM EST to discuss results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315223005024/0001493152-23-005024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315223005024/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-005024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer